Telesis Bio to Present at the Cowen 43rd Annual Healthcare Conference

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will participate in a fireside chat with Steven Mah at the 43rd Annual Cowen Healthcare Conference on Monday, March 6th at 12:50 PM Eastern Time/ 9:50AM Pacific Time. Additionally, Todd will participate in a ‘Synthetic Biology Enabling Technologies Panel’ on Tuesday, March 7th at 4:40pm Eastern time / 1:40 pm Pacific Time.

The fireside chat and panel discussion will both be webcast live and can be accessed through a link on the investors section of Telesis Bio’s investor relations website at https://ir.telesisbio.com/. An archived replay of each webcast will be available for 30 days following the event.

About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.

Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

Contact:
Jen Carroll
Vice President of Investor Relations
jen.carroll@telesisbio.com

Staff

Recent Posts

FendX Technologies Announces Second Closing of Non-Brokered Private Placement and Announces Further Upsizing to $2 million

Oakville, Ontario--(Newsfile Corp. - March 25, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

1 hour ago

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30…

1 hour ago

Brüush Receives Additional Delisting Notification to Address at Hearing

VANCOUVER, BC / ACCESSWIRE / March 25, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the…

1 hour ago

PillSafe Spearheads Solutions to Opioid Crisis With Revolutionary Technology

Government and industry have tried and failed to stem the overdose epidemic for more than…

4 hours ago

The Assistance Fund Opens New Program for Post-Traumatic Stress Disorder

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Post-Traumatic Stress…

4 hours ago